Search by Drug Name or NDC

    NDC 00173-0892-63 Nucala 100 mg/mL Details

    Nucala 100 mg/mL

    Nucala is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is MEPOLIZUMAB.

    Product Information

    NDC 00173-0892
    Product ID 0173-0892_6aaacdeb-43d4-4367-9d37-a9d6876344f1
    Associated GPIs 4460405500D530 4460405500E530
    GCN Sequence Number 079829
    GCN Sequence Number Description mepolizumab AUTO INJCT 100 MG/ML SUBCUT
    HIC3 Z20
    HIC3 Description INTERLEUKIN-5 (IL-5) ANTAGONISTS, MAB
    GCN 46414
    HICL Sequence Number 042775
    HICL Sequence Number Description MEPOLIZUMAB
    Brand/Generic Brand
    Proprietary Name Nucala
    Proprietary Name Suffix n/a
    Non-Proprietary Name mepolizumab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 100
    Active Ingredient Units mg/mL
    Substance Name MEPOLIZUMAB
    Labeler Name GlaxoSmithKline LLC
    Pharmaceutical Class Interleukin-5 Antagonist [EPC], Interleukin-5 Antagonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761122
    Listing Certified Through 2024-12-31

    Package

    NDC 00173-0892-63 (00173089263)

    NDC Package Code 0173-0892-63
    Billing NDC 00173089263
    Package 1 SYRINGE in 1 CARTON (0173-0892-63) / 1 mL in 1 SYRINGE
    Marketing Start Date 2019-06-06
    NDC Exclude Flag N
    Pricing Information N/A